tiprankstipranks
Advertisement

DBEU - ETF AI Analysis

Compare

Top Page

DBEU

Xtrackers MSCI Europe Hedged Equity ETF (DBEU)

Rating:63Neutral
Price Target:
DBEU, the Xtrackers MSCI Europe Hedged Equity ETF, has a solid overall rating driven mainly by high-quality European leaders like AstraZeneca, Novartis, HSBC, and ASML, which show strong financial performance, positive earnings outlooks, and generally supportive technical trends. Defensive giants such as Nestlé and stable industrial and energy names like Siemens and Shell add balance and stability, though some holdings face valuation concerns, mixed technical signals, or growth and cash flow challenges that prevent the fund from scoring even higher. A key risk factor is its concentration in large European companies and sectors such as healthcare, financials, and industrials, which can expose investors to region-specific and sector-specific economic and regulatory shifts.
Positive Factors
Solid Recent Performance
The ETF has shown steady gains over the past month, three months, and year-to-date, indicating positive recent momentum.
Geographic Diversification Across Europe
Holdings spread across major European markets like the UK, France, Germany, Switzerland, and others help reduce the impact of weakness in any single country.
Balanced Sector Mix
Exposure to a range of sectors, including financials, industrials, health care, and technology, provides a more balanced risk profile than focusing on just one industry.
Negative Factors
Moderate Expense Ratio
The fund’s expense ratio is not especially low, meaning fees may be higher than some cheaper index ETFs and can slightly reduce long-term returns.
Mixed Performance Among Top Holdings
While some leading positions like ASML and Siemens have performed strongly, others such as SAP, Nestlé, and AstraZeneca have been weaker, creating uneven contribution to returns.
High Weight in Financials
A relatively large allocation to financial stocks increases the fund’s sensitivity to banking and interest-rate related risks in Europe.

DBEU vs. SPDR S&P 500 ETF (SPY)

DBEU Summary

DBEU is an ETF that follows the MSCI Europe U.S. Dollar Hedged Index, giving you broad exposure to large and mid-sized companies across many European countries while trying to reduce the impact of currency swings between the euro and the U.S. dollar. It holds well-known names like Nestlé and AstraZeneca, along with many banks, industrial firms, and health care companies. Someone might invest in DBEU to diversify beyond the U.S. and tap into Europe’s long-term growth while limiting currency risk. A key risk is that European stock prices can still go up and down with the overall market and regional economies.
How much will it cost me?The Xtrackers MSCI Europe Hedged Equity ETF (DBEU) has an expense ratio of 0.45%, meaning you’ll pay $4.50 per year for every $1,000 invested. This is slightly higher than average for passively managed ETFs because it includes a currency hedging strategy to reduce the impact of exchange rate fluctuations.
What would affect this ETF?The DBEU ETF could benefit from positive economic growth in Europe, particularly in sectors like financials and industrials, which make up a significant portion of its holdings. Additionally, its currency hedging strategy provides protection against euro-to-dollar fluctuations, which can stabilize returns for U.S. investors. However, potential risks include economic slowdowns in Europe, regulatory changes affecting key industries, or geopolitical tensions that could impact the performance of its top holdings like ASML and Nestlé.

DBEU Top 10 Holdings

DBEU leans heavily on Europe’s healthcare and financial giants, with drugmakers like Novartis and AstraZeneca providing a steadier hand while Roche has been losing steam and weighing on returns. Big banks such as HSBC are also lagging, adding a bit of drag. On the brighter side, energy names like Shell and TotalEnergies are doing the heavy lifting, rising on stronger commodity sentiment. ASML sits at the crossroads of Europe’s tech story with mixed but generally supportive momentum. Overall, it’s a developed Europe play, not a global one.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
ASML Holding NV3.75%$25.27M€448.98B74.19%
76
Outperform
AstraZeneca2.12%$14.26M$285.44B20.00%
80
Outperform
Novartis AG2.09%$14.09MCHF221.00B16.50%
80
Outperform
Roche Holding AG2.05%$13.77MCHF242.59B12.65%
73
Outperform
HSBC Holdings1.93%$12.96M£203.18B33.43%
80
Outperform
Nestlé SA1.89%$12.73MCHF189.31B-5.64%
71
Outperform
Shell (UK)1.82%$12.28M£188.72B23.10%
73
Outperform
SAP SE1.43%$9.61M€175.18B-40.04%
66
Neutral
Siemens1.37%$9.25M€161.07B-11.49%
74
Outperform
TotalEnergies SE1.18%$7.94M€162.56B30.49%
78
Outperform

DBEU Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
49.57
Negative
100DMA
48.63
Positive
200DMA
46.71
Positive
Market Momentum
MACD
-0.35
Negative
RSI
53.98
Neutral
STOCH
94.58
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For DBEU, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 48.39, equal to the 50-day MA of 49.57, and equal to the 200-day MA of 46.71, indicating a neutral trend. The MACD of -0.35 indicates Negative momentum. The RSI at 53.98 is Neutral, neither overbought nor oversold. The STOCH value of 94.58 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DBEU.

DBEU Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$667.45M0.45%
63
Neutral
$28.10B0.06%
62
Neutral
$669.20M0.07%
63
Neutral
$140.99M0.80%
57
Neutral
$112.25M0.25%
63
Neutral
$105.56M0.09%
64
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DBEU
Xtrackers MSCI Europe Hedged Equity ETF
49.25
10.66
27.62%
VGK
Vanguard FTSE Europe ETF
SPEU
SPDR Portfolio Europe ETF
FEUZ
First Trust Eurozone AlphaDEX ETF
GSEU
Goldman Sachs ActiveBeta Europe Equity ETF
FLEE
Franklin FTSE Europe ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement